Shots: The P-III KEYNOTE-062 (NCT02494583) study involves assessing of Keytruda as monothx. and in combination with CT (cisplatin/5-fluorouracil/capecitabine) & CT as monthx. in 763 patients for the 1L treatment of […]readmore
Tags : KEYNOTE-062
Latest Posts
Categories
Related Topics
AbbVie
Acceptance
Acquire
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Boehringer Ingelheim
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Lilly
Merck
Novartis
P-III
patients
Pfizer
receives
Regeneron
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
Treat
Treatment
US